{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:22:42Z","timestamp":1780467762121,"version":"3.54.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Washington University Neuromuscular Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Myopathies during chronic graft-versus-host disease (cGvHD) are\u00a0syndromes for which tissue targets and mechanisms of muscle damage remain incompletely defined. This study reviewed, and pathologically analyzed, 14 cGvHD myopathies, comparing myopathology to other immune myopathies. Clinical features in cGvHD myopathy included symmetric, proximal weakness, associated skin, gastrointestinal and lung disorders, a high serum aldolase (77%), and a 38% 2-year survival. Muscle showed noninflammatory pathology involving all 3 tissue components. Perimysial connective tissue had damaged structure and histiocytic cells. Vessel pathology included capillary loss, and reduced \u03b1-l-fucosyl and chondroitin sulfate moieties on endothelial cells. Muscle fibers often had surface pathology. Posttranslational glycosylation moieties on \u03b1-dystroglycan had reduced staining and abnormal distribution in 86%. Chondroitin-SO4 was reduced in 50%, a subgroup with 3-fold longer times from transplant to myopathy, and more distal weakness. cGvHD myopathies have noninflammatory pathology involving all 3 tissue components in muscle, connective tissue, small vessels, and myofibers. Abnormal cell surface glycosylation moieties are common in cGvHD myopathies, distinguishing them from other immune myopathies. This is the first report of molecular classes that may be immune targets in cGvHD. Disordered cell surface glycosylation moieties could produce disease-related tissue and cell damage, and be biomarkers for cGvHD features and activity.<\/jats:p>","DOI":"10.1093\/jnen\/nlz111","type":"journal-article","created":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T10:10:49Z","timestamp":1575540649000},"page":"102-112","source":"Crossref","is-referenced-by-count":11,"title":["Chronic Graft Versus Host Myopathies: Noninflammatory, Multi-Tissue Pathology With Glycosylation Disorders"],"prefix":"10.1093","volume":"79","author":[{"given":"Alan","family":"Pestronk","sequence":"first","affiliation":[{"name":"Departments of Neurology, and Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri (AP)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,10]]},"reference":[{"key":"2024032523300129900_nlz111-B1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1189\/jlb.4RU0615-254RR","article-title":"Cellular and molecular mechanisms in graft-versus-host disease","volume":"99","author":"Zhang","year":"2016","journal-title":"J Leukoc Biol"},{"key":"2024032523300129900_nlz111-B2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","article-title":"The biology of chronic graft-versus-host disease: A task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease","volume":"23","author":"Cooke","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032523300129900_nlz111-B3","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"key":"2024032523300129900_nlz111-B4","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"2024032523300129900_nlz111-B5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.bbmt.2014.10.022","article-title":"Center for International Blood and Marrow Transplant Research chronic graft versus-host disease risk score predicts mortality in an independent validation cohort","volume":"21","author":"Arora","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032523300129900_nlz111-B6","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/mus.26341","article-title":"Inflammatory myopathies after allogeneic stem cell transplantation","volume":"58","author":"New-Tolley","year":"2018","journal-title":"Muscle Nerve"},{"key":"2024032523300129900_nlz111-B7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00005792-199609000-00004","article-title":"Polymyositis as a manifestation of chronic graft-versus-host disease","volume":"75","author":"Parker","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2024032523300129900_nlz111-B8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/keg025","article-title":"Polymyositis as a manifestation of chronic graft-versus-host disease","volume":"42","author":"Stevens","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"2024032523300129900_nlz111-B9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bmt.2008.297","article-title":"Fasciitis and myositis: An analysis of muscle-related complications caused by chronic GVHD after allo-SCT","volume":"43","author":"Oda","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"2024032523300129900_nlz111-B10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032523300129900_nlz111-B11","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1212\/NXI.0000000000000434","article-title":"Immune myopathies with perimysial pathology (IMPP): Clinical and laboratory features","volume":"5","author":"Bucelli","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024032523300129900_nlz111-B12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.21651","article-title":"Vascular pathology in dermatomyositis and anatomic relations to myopathology","volume":"42","author":"Pestronk","year":"2010","journal-title":"Muscle Nerve"},{"key":"2024032523300129900_nlz111-B13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/jnnp.68.4.472","article-title":"Myopathy with anti-Jo-1 antibodies: Pathology in perimysium and neighbouring muscle fibres","volume":"68","author":"Mozaffar","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032523300129900_nlz111-B14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","article-title":"Myopathy with antibodies to the signal recognition particle: Clinical and pathological features","volume":"73","author":"Miller","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032523300129900_nlz111-B15","volume-title":"Muscle Biopsy Stains","author":"Pestronk"},{"key":"2024032523300129900_nlz111-B16","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: Pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2024032523300129900_nlz111-B17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"JND"},{"key":"2024032523300129900_nlz111-B18","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"2024032523300129900_nlz111-B19","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.50.2.526","article-title":"Steroid-responsive myopathy with deficient chondroitin sulfate C in skeletal muscle connective tissue","volume":"50","author":"Al-Lozi","year":"1998","journal-title":"Neurology"},{"key":"2024032523300129900_nlz111-B20","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"key":"2024032523300129900_nlz111-B21","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(02)08907-9","article-title":"Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease","volume":"359","author":"Biedermann","year":"2002","journal-title":"Lancet"},{"key":"2024032523300129900_nlz111-B22","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/bmt.2017.121","article-title":"Endothelial damage is aggravated in acute GvHD and could predict its development","volume":"52","author":"Mir","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"2024032523300129900_nlz111-B23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40478-018-0512-6","article-title":"Diffuse microvascular C5b-9 deposition is a common feature in muscle and nerve biopsies from diabetic patients","volume":"6","author":"Yell","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"2024032523300129900_nlz111-B24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/jnnp.2008.161448","article-title":"High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology","volume":"80","author":"Nozaki","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032523300129900_nlz111-B25","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/brain\/awm212","article-title":"Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan","volume":"130","author":"Godfrey","year":"2007","journal-title":"Brain"},{"key":"2024032523300129900_nlz111-B26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.mam.2016.07.003","article-title":"Mechanistic aspects of the formation of alpha-dystroglycan and therapeutic research for the treatment of alpha-dystroglycanopathy: A review","volume":"51","author":"Taniguchi-Ikeda","year":"2016","journal-title":"Mol Aspects Med"},{"key":"2024032523300129900_nlz111-B27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/jnnp.73.1.89","article-title":"A Japanese case of steroid responsive myopathy with deficient chondroitin sulphate","volume":"73","author":"Yabe","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032523300129900_nlz111-B28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1055\/s-0036-1586265","article-title":"Myasthenia gravis","volume":"36","author":"Drachman","year":"2016","journal-title":"Semin Neurol"},{"key":"2024032523300129900_nlz111-B29","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fneur.2019.00516","article-title":"Autoimmune channelopathies at neuromuscular junction","volume":"10","author":"Huang","year":"2019","journal-title":"Front Neurol"},{"key":"2024032523300129900_nlz111-B30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp-2017-315736","article-title":"IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy","volume":"88","author":"Campagnolo","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2024032523300129900_nlz111-B31","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jns.12311","article-title":"A population-based and cross-sectional study of the long-term prognosis in multifocal motor neuropathy","volume":"24","author":"Al-Zuhairy","year":"2019","journal-title":"J Peripher Nerv Syst"},{"key":"2024032523300129900_nlz111-B32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.bbmt.2018.03.008","article-title":"Steroid refractory chronic graft-versus-host disease: Cost-effectiveness analysis","volume":"24","author":"Yalniz","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024032523300129900_nlz111-B33","article-title":"Safety and efficacy of rituximab-based first line treatment of chronic GVHD","author":"Solomon","journal-title":"Bone Marrow Transplant"},{"key":"2024032523300129900_nlz111-B34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/1744666X.2018.1463159","article-title":"The search for drug-targetable diagnostic, prognostic and predictive biomarkers in chronic graft-versus-host disease","volume":"14","author":"Ren","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2024032523300129900_nlz111-B35","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/NEN.0000000000000132","article-title":"Regional ischemic immune myopathy: A paraneoplastic dermatomyopathy","volume":"73","author":"Cai","year":"2014","journal-title":"J Neuropathol Exp Neurol"},{"key":"2024032523300129900_nlz111-B36","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ajpath.2015.11.010","article-title":"Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: Common interferon signature but distinct NOS2 expression","volume":"186","author":"Allenbach","year":"2016","journal-title":"Am J Pathol"},{"key":"2024032523300129900_nlz111-B37","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.118.035898","article-title":"Immune checkpoint inhibitor-associated myositis","volume":"138","author":"Anquetil","year":"2018","journal-title":"Circulation"},{"key":"2024032523300129900_nlz111-B38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","article-title":"Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation","volume":"25","author":"Ijaz","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Neuropathology &amp; Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/79\/1\/102\/31495704\/nlz111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnen\/article-pdf\/79\/1\/102\/31495704\/nlz111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:40:49Z","timestamp":1711410049000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnen\/article\/79\/1\/102\/5653098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12,10]]},"published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnen\/nlz111","relation":{},"ISSN":["0022-3069","1554-6578"],"issn-type":[{"value":"0022-3069","type":"print"},{"value":"1554-6578","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,12,10]]}}}